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Abstract
Alzheimer's disease (AD) is the most common cause of dementia in the elderly. In the pathogenesis of AD a pivotal
role is played by two neurotoxic proteins that aggregate and accumulate in the central nervous system: amyloid beta
and hyper-phosphorylated tau. Accumulation of extracellular amyloid beta plaques and intracellular hyper-
phosphorylated tau tangles, and consequent neuronal loss begins 10–15 years before any cognitive impairment. In
addition to cognitive and behavioral deficits, sensorial abnormalities have been described in AD patients and in some
AD transgenic mouse models. Retina can be considered a simple model of the brain, as some pathological changes
and therapeutic strategies from the brain may be observed or applicable to the retina. Here we propose new retinal
biomarkers that could anticipate the AD diagnosis and help the beginning and the follow-up of possible future
treatments. We analyzed retinal tissue of triple-transgenic AD mouse model (3xTg-AD) for the presence of pathological
hallmarks during disease progression. We found the presence of amyloid beta plaques, tau tangles,
neurodegeneration, and astrogliosis in the retinal ganglion cell layer of 3xTg-AD mice, already at pre-symptomatic
stage. Moreover, retinal microglia in pre-symptomatic mice showed a ramified, anti-inflammatory phenotype which,
during disease progression, switches to a pro-inflammatory, less ramified one, becoming neurotoxic. We hypothesize
retina as a window through which monitor AD-related neurodegeneration process.
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia, accounting for 60–70% of all dementia cases.
AD is a progressive neurodegenerative disorder causing
irreversible deterioration in cognitive functions, second-
ary to neuronal cell death and brain atrophy1,2. The main
pathological and diagnostic features are the accumulation
of two proteins: amyloid-β (Aβ) peptide, generated from
the amyloid precursor protein (APP), which aggregates
into extracellular plaques, and hyper-phosphorylated tau
(pTau), which forms intracellular neurofibrillary tangles.
Evidence now implies that neuropathological changes
involving the accumulation of Aβ occur up to 10–15 years
prior to the emergence of clinical symptoms, emphasizing
the importance of developing new methods for early
diagnosis3. Currently, diagnosis is based primarily upon
cognitive assessments of patients presenting symptomatic
features of cognitive and behavioral changes4,5. Computed
tomography (CT) and/or magnetic resonance imaging
(MRI) are frequently used in the initial diagnosis of cases
where cognitive AD signs are present, whereas positron
emission tomographic (PET) amyloid imaging is less fre-
quently included, mainly where confirmation is needed6.
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However, PET is not applicable for use in population-
wide screening, owing to the relatively high cost of this
test. Besides PET amyloid imaging, cerebrospinal fluid
(CSF) pathophysiological markers, including Aβ1–42,
total tau, and pTau, have also shown high specificity in
confirming AD pathophysiology. CSF biomarkers in AD
and mild cognitive impairment have been increasingly
used showing that lower CSF levels of Aβ42 and higher
CSF levels of total tau and pTau compared with controls
were associated to severe AD7. However, lumbar puncture
is an invasive analysis, and its use varies between coun-
tries. A desirable matrix for AD biomarker detection
could be through plasma, however no significant differ-
ences of the concentration of Aβ markers in AD and
control subjects have been found between plasma or
serum7.
Moreover, on the therapeutic side, clinical trials of AD
drugs have been hindered, in part, by the limited number
of biomarkers that can accurately diagnose this disease,
and reliably monitor disease progression and response to
treatment. In this framework currently available bio-
markers are expensive, invasive, or both, and have been
concentrated on brain and CSF targets.
The retina and the brain have been demonstrated to be
associated to over a range of neurological diseases and
respond similarly to neuropathological conditions8.
Despite its peripheral location, the retina is part of the
central nervous system. Retinal cells are arranged in dif-
ferent layers: the outer layer (OL) containing photo-
receptors and the inner layer (IL) containing various cell
types: interneurons and retinal ganglion cells (RGC),
which send their axons to the thalamus. Glial cells are also
found in the retina; astrocytes and microglia are usually
restricted to the RGC layer and participate in the control
of tissue homeostasis (Supplementary Fig 1). Visual defi-
cits and pathological changes have been described in the
retinas of AD patients; indeed, retinal abnormalities such
as extensive loss of retinal ganglion cell neurons
(RGC)9,10, reduced thickness of retinal nerve fiber layer
(NFL)11, and reduced retinal blood flow12 have been
observed in AD patients.
The advantages of using retinal screening for diagnosing
of probable AD rely on low costs, easy visual accessibility
of the tissue, and the non-invasive nature of the tests. It
has been recently reported that Aβ accumulates in eyes
from both human AD and APP/PS1-transgenic mouse
models at late disease stage, and retinal plaques have been
correlated with plaque load in the brain and vascular
abnormalities13. However, these changes have been found
also in retinal glaucoma14,15 and a multifactorial analysis
of retinal tissue is needed to use the eye as potential target
for AD diagnosis, especially at pre-symptomatic stage.
Recent findings also demonstrated the alteration in the
level of endogenous retinal Tau of 3 and 6 months old
3xTg mice, and retina neurodegeneration, measured as a
reduction in the number of RGC, starting from 6 months
of age16. However, while all these reports describe AD
signs in the retinal tissue of symptomatic mice, no data
report up to now, retinal abnormalities in pre-
symptomatic mice.
Another important factor in neurodegenerative diseases
is the role of neuroinflammation; although neuroin-
flammatory responses are commonly described in the
brain of AD patients and animal models, only few reports
describe retinal glia alterations in AD. Retinal glial cells,
including astrocytes and microglia, are responsible for the
maintenance of the retinal microenvironment, trophic
and structural support, regulation of homeostatic func-
tions and an appropriate immune response, fundamental
roles for the proper functioning of the retina. Retinal
astrocytes, with flattened cell bodies and fibrous radiating
processes are not uniformly distributed along the retina,
with higher density in the optic nerve region. Indeed, they
envelop the optic nerve axons and blood vessels to
maintain retinal brain barrier integrity. Increase of glial
fibrillary acidic protein (GFAP) immunoreactivity, indi-
cative of astrogliosis, has been reported in the RGC layer
of AD patient biopsies and in the late-symptomatic stages
of 3xTg-AD mice17.
Like in the nervous system, microglia cells are the
resident monocytes of the retina, and they are mainly
located in plexiform layers and can undergo different
activation states and phenotypes, depending on the sti-
mulus they enter in contact with. Resting microglia is
continuously surveying parenchyma and, in response to
stress conditions, adopts a reactive phenotype, char-
acterized by changes in the expression of pro and/or anti-
inflammatory markers, phagocytic activity, and morphol-
ogy18. In the brain of AD animal models, microglia initi-
ally reacts against neuronal damage trying to resolve
inflammation, displaying an anti-inflammatory pheno-
type; then during disease progression, microglia acquires
and remains in a pro-inflammatory phenotype char-
acterized, among other, by the production of reactive
oxygen and nitrogen species, that cause themselves neu-
ronal death. Increased microglia reactivity in the retina
has been reported in bioptic tissues of AD patients19 and
in late-stage animal models20.
Thus, the idea of using the eye as an extension of the
brain for non-invasive visualization of AD pathology is
rapidly growing; however, there is still controversy on the
possible biomarkers useful to early diagnose and poten-
tially monitor development and treatment of AD. Here we
investigated retinal biomarkers analyzing retinal tissue of
3xTg-AD mouse model in a longitudinal study starting
from young, pre-symptomatic mice. We report that in the
RCG layer Aβ plaques and pTau tangles, together with
cleaved caspase-3 and glia (astrocytes and microglia)
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activation are detectable in the retina of pre-symptomatic




Procedures using laboratory animals were in accordance
with the Italian and European guidelines and were
approved by the Italian Ministry of Health (no. 457/
2017–PR) in accordance with the guidelines on the ethical
use of animals from the European Communities Council
Directive of 20 September 2010 (2010/63/UE). All efforts
were made to minimize suffering and number of animals
used. The 3xTg-AD mice bearing the human mutations in
the genes encoding presenilin 1 (PS1M146V), amyloid
precursor protein (APPSwe), and tau (MAPTP301L)21,
and age-matched wild-type controls 129sv/C57Bl6 (non-
Tg) were purchased from Jackson Laboratories (Bar
Harbor, ME) and maintained in our animal facility.
Experiments were performed at different PNWs
(5–10–20 PNWs for pre-symptomatic; 30-32-40 for early-
symptomatic; 50–72 for late-symptomatic mice), corre-
sponding to pre, early, and late-symptomatic mice in line
with the time course previously reported22,23. Results of
each group were compared with the corresponding age-
matched non-Tg mice.
Immunofluorescence analysis
Mice at different ages were killed by a chloral hydrate
overdose (400 mg/kg, i.p.) and then intracardially perfused
with PBS and 4% PFA; brains and eyes were removed and
kept in 4% PFA solution; after 16 h, tissues were passed
into a 30% sucrose solution and, after precipitation, they
were frozen in isopentane at −80 °C. Sections (20–40 μm)
were obtained by a Leica cryostat and subsequently
treated for immunofluorescence experiments. Briefly, sli-
ces were treated 40 min with a warm solution of antigen
retrieval (10 mM Na-citrate, 0.05% Tween 20, pH 6.0, 90 °
C) to facilitate and increase the exposure of the antigen
(when required) and they were then incubated 45min in a
blocking solution (3% goat serum and 0.3% Triton X-100
in PBS). Primary antibodies were then incubated for 16 h
at 4 °C in a solution with 1% of goat serum and 0.1% of
Triton X-100 at different concentrations (anti-Iba1, Wako
#019-19741, 1: 500; anti-cleaved caspase-3, Cell Signaling
Technology, Asp175, 1:500; anti-Aβ, Cell Signaling,
D54D2, 1:100; anti-GFAP, Novus Biologicals, #NB300-
141, 1:500; anti-PHF-Tau, Thermo Scientific, #MN1020,
1:100; anti-Tuj1, Covance, #MMS-435P, 1:500). The day
after slices were left 30 min at room temperature and,
after three washes in PBS, sections were stained with the
fluorophore-conjugated antibody and Hoechst for nuclei
visualization for 45min, mounted and analyzed by means
of a confocal microscope (FV10i, Olympus).
Microglia density analysis
For the analysis of microglia cells density, in slices
immunolabeled for Iba1, a well-known microglia marker,
images were acquired using an inverted confocal laser
scanning microscope (FV10i Olympus) with a ×60 water
immersion objective and a z-step of 0.5 µm. Image pro-
cessing was performed using ImageJ software in order to
create maximum intensity projections of z-series stacks.
The number of Iba1+ microglia was counted and calcu-
lated as cells per volume (mm3). Briefly, the number of
cells within each acquired field was divided by the area of
the slice multiplied by its thickness. The value obtained
was multiplied by 109 to get the number of microglial cells
present in a mm3 of the slice.
Astrogliosis analysis
Confocal images of GFAP staining were acquired to
evaluate the status of astrogliosis. Images were analyzed
by Metamorph image analysis software to obtain a z-
projection based on the maximal intensity signal. Astro-
gliosis was quantified as fluorescence intensity: the
threshold was adjusted to accurately represent the num-
ber of GFAP-positive cell processes and data were
expressed as area occupied by fluorescent cells vs total
slice area.
Analysis of neurodegeneration
To evaluate neurodegeneration, we counted the number
of cleaved caspase-3-positive cells. For the retina, the
whole slice was considered, while for the brain only the
hippocampal region was examined. The images acquired
with a fluorescence microscope (Nikon Eclipse Ti, ×40
objective) were analyzed with the Metamorph software.
The number of cleaved caspase-3-positive cells was then
divided by the total number of ganglion neurons within
each retina slice (or by the area of the hippocampal region
in the case of the brain) and expressed as a percentage.
Microglia morphological analysis
For morphological analysis of microglia cells, images
were acquired using an inverted confocal laser scanning
microscope (FV10i Olympus) with a ×60 water immersion
objective and a z-step of 0.5 µm with slices immunola-
beled for Iba1. Maximal intensity projections of Iba1
confocal images were analyzed to obtain morphological
indicators of cell complexity. Image processing was per-
formed using ImageJ software. Only cells whose cell body
and processes were fully contained in the slice were
included in the analysis. The soma area was determined
by drawing a line around the cell body, by using the
freehand selection tool. The extent of microglia ramifi-
cation was quantified by measuring the area circum-
scribed by the distal ends of each process, using the
polygon selection tool. For skeleton analysis, the
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maximum intensity projection was enhanced to
visualize all microglia processes; this was followed by
noise de-speckling to eliminate single-pixel background
fluorescence. The resulting image was converted to
a binary image and then skeletonized, using the
corresponding ImageJ plug-in. Total processes, end point,
and junction number were calculated from the skeleto-
nized image.
Microglia cells sorting from mice retinas
Single cell suspension was stained with CD11b PE and
CD45.2 APC-eFluor780 anti-mouse antibodies (eBios-
ciences) and isolated using a FACSAriaIII (BD Bios-
ciences) equipped with a 561 nm and a 633 nm laser and
FACSDiva software (BD Biosciences version 6.1.3). Data
were analyzed using a FlowJo software (Tree Star).
According to the gate strategy showed in Fig. 3d, cells first
gated based on forward and side scatter area (FSC-A and
SSC-A) plot were then detected for doublet exclusion
both in FSC and SSC parameters (height vs. area). CD45.2
APC-eFluor780-positive cells were then sorted based on
CD11b PE expression levels. To reduce stress to retina
samples, cells were isolated in gentle conditions using a
ceramic nozzle of size 100 µm, a low sheath pressure of
19.84 pound force per square inch (psi) that maintain the
sample pressure at 18.96 psi and an acquisition rate of
maximum 3000 events/s.
Real-time PCR analysis
Upon sorting, enriched samples were used for total
RNA isolation. Briefly, cells were lysed in Trizol (Invi-
trogen, CA, USA), retrotranscripted, and analyzed by real-
time PCR as described in ref. 24. Primers used are listed in
Suppl Table 1.
Results
Retinal and hippocampal neuron degeneration starts at
pre-symptomatic stage in 3xTg-AD mice
In AD brain, the onset of neurodegenerative process
and neuronal apoptosis has been linked to the caspase-3-
mediated cleavage of AD-linked proteins (APP and pre-
senilins), and AD patients exhibited significant increase in
synaptic procaspase-3 and active caspase-3 expression
levels compared with age-matched controls25. We first
asked whether signs of apoptotic neurons could be found
in the retina and in the brain of 3xTg-AD mice at different
stages of the disease. For this purpose, slices of 3xTg-AD
mice were analyzed along disease progression, namely at
pre-symptomatic (5–20 post-natal weeks, PNWs), early-
symptomatic (30–40 PNWs), and late-symptomatic
(50–80 PNWs) stages and compared to those from age-
matched non-Tg controls. These time windows have been
selected because they correspond, respectively, to the
appearance of anatomical, electrophysiological, and
cognitive signs typical of AD in the brain of this mouse
model22,23.
We found, by confocal immunofluorescence analysis,
that cleaved caspase-3 punctate staining was present in
the RGC layer (Inner Layer; IL) already at five PNWs
(Fig. 1a, left red dots). Labeling with an antibody against
tubulin isoform βIII (TUJ1), an RGC-specific marker that
strongly labels the soma of these neurons, confirmed
caspase-3 localization near the cell nucleus (Fig. 1c, green
dots). As reported in Fig. 1b, the percentage of caspase-3-
positive cells increased during AD progression and was
significantly higher respect to what was observed in the
retina of age-matched non-Tg mice (Fig. 1a, c).
Despite neuronal loss has been reported in the brain of
different AD mouse models starting from 30 PNWs26,27,
no data are available for the 3xTg-AD model. To compare
the results obtained in the retina with brain neuronal loss,
brain slices from the same group of mice were analyzed
for cleaved caspase-3 expression in the hippocampus.
Confocal immunofluorescence analysis revealed that
neurodegeneration, measured as cleaved caspase-3
punctate staining, was present in the hippocampus
already at five PNWs and displayed similar time course to
the one observed in the retina (Fig. 1d).
These results indicated that neuronal apoptosis starts in
the AD retina, predominantly in RGC layer, at pre-
symptomatic stage and that the time course of neurode-
generation runs parallel to what is observed in the brain.
Glial activation precedes symptoms onset in brain and
retina of 3xTg-AD mice
Confocal analysis of GFAP staining in the 3xTg-AD
mice retina showed marked astrogliosis (measured as
fluorescence intensity) already at 5–10 PNWs (Fig. 2a)
with reactive astrocytes present in the granular cell layer,
as expected. GFAP staining was higher in the 3xTg-AD
retina at pre and early-symptomatic AD stages, becoming
similar to non-Tg retina at late stage (Fig. 2b).
Immunofluorescence to detect microglia cells (Iba1
positive) in the retina revealed that microglia were mainly
found in two layers: the inner plexiform and the outer
plexiform layers (Fig. 2c). We found that microglia cell
density was similar in the retina of control and 3xTg-AD
mice at 5–40 PNWs, while its density strongly increased
in late-symptomatic AD mice (Fig. 2d) respect to age-
matched controls.
Thus, we deeply investigated microglia phenotype in the
retina of 3xTg-AD mice characterizing microglia mor-
phology and activation state-associated transcripts by
real-time PCR. Parallel experiments were performed in
non-Tg age-matched controls.
Skeletonized images obtained from confocal z-stack
acquisitions (Fig. 3a, b) revealed that at 5–10 PNWs ret-
inal 3xTg-AD microglia displayed increased arborization
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compared to non-Tg, while no differences were observed
in the soma area (data not shown). Consistently, 3xTg-AD
microglia cells are characterized by higher scanning
domain (Fig. 3c, first panel), reflecting an increase of the
arborization area with respect to the cell body area and
suggesting differences in microglia basal scanning prop-
erties. Indeed, 3xTg-AD cells showed higher number
of branches, branch points, and triple junctions
compared to non-Tg cells, demonstrating that at pre-
symptomatic stage 3xTg-AD microglia cells are more
ramified (Fig. 3c, third and fourth panel). Longitudinal
analysis during disease progression demonstrated that
these differences disappeared in early-symptomatic mice,
indicating similar morphology in 3xTg and non-Tg
microglia (Fig. 3c, second panel). Conversely, in the
retina of late-symptomatic AD mice, microglia became
less ramified respect to non-Tg controls, with a mor-
phological index becoming lower during disease
progression (Fig. 3c).
It is known that the M/MΦ cell population in the brain
is deeply involved in AD-related neurodegenerative pro-
cess and its activation state changes during disease pro-
gression28–30; we thus analyzed microglia phenotype in
the retina of pre-symptomatic and early-symptomatic AD
mice and age-matched controls.
Microglia cells were stained using CD11b and CD45.2
antibodies and sorted by a FACSAriaIII; the number of
microglia cells in the retina, identified as Cd11b+
Cd45low cells (Fig. 3d), was comparable in the two gen-
otypes (960 ± 150 cells in non-Tg, 1100 ± 100 in 3xTg-AD
mice at 5–10 PNWs; 660 ± 100 non-Tg; 720 ± 150 3xTg-
AD at 20–40 PNWs; n= 6 mice in each group, p= 0.1,
two-way ANOVA) confirming immunofluorescence data
(Fig. 2d). Data in Fig. 3e indicated that microglia cells
sorted from the retina of 5–10 PNWs 3xTG-AD mice
expressed higher level of some typical anti-inflammatory
neuroprotective genes (Ym1 and CD206) respect to their
age-matched controls. During disease progression, these
Fig. 1 Retinal neurodegeneration starts at pre-symptomatic stage in 3xTg-AD mice. a Retinal slices were immunolabeled with anti-cleaved
caspase-3 antibody (red) and Hoechst for nuclei visualization (blue) at different ages of 3xTg-AD and non-Tg mice. b Percentage of cleaved caspase-
3-positive cells (**p < 0.01 pre vs late; *p < 0.05 pre vs early; p= 0.12 early vs late; n= 16 fields/four slices for each condition; two-way ANOVA, Holm-
Sidak) and comparison with age-matched non-Tg mice (##p < 0.01; n= 16 fields/four slices for each condition; two-way ANOVA, Holm-Sidak). c
Representative image of retinal slice immunolabeled with anti-cleaved-caspase-3 antibody (green), anti Tuj-1 (red), and Hoechst for nuclei
visualization (blue). d Percentage of cleaved caspase-3-positive cells (**p < 0.001 pre vs late; *p < 0.05 pre vs early; p= 0.15 early vs late; n= 16 fields/
four slices for each condition; two-way ANOVA, Holm-Sidak) and comparison with age-matched non-Tg mice in hippocampal area (##p < 0.01; n= 16
fields/four slices for each condition; two-way ANOVA, Holm-Sidak)
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genes undergo a significant reduction of expression in
3xTg-AD retina respect to their control. Conversely, pro-
inflammatory, neurotoxic genes (iNOS, il1β), whose
expression is low at pre-symptomatic AD stage, are
remarkably increased during disease progression (Fig. 3f).
It should be noted that this trend is not common to all the
pro- and anti-inflammatory markers analyzed; in fact,
TNF alpha (Fig. 3f) and Fizz-1 (Fig. 3e) showed opposite
modulation during disease progression.
We also analyzed the expression level of the triggering
receptor expressed on myeloid cells 2 (TREM-2), a mar-
ker expressed by microglia associated with neurodegen-
erative diseases31 in the retina. We found higher
expression of TREM-2 mRNA in retinal microglia along
the course of the disease (Fig. 3g), confirming, also in the
3xTg-AD model, the involvement of TREM-2 regulation
in AD progression.
Altogether these data indicated that at pre-symptomatic
AD stage, retinal microglia cells acquire a ramified, anti-
inflammatory phenotype which can account for an
increased tissue monitoring in response to first disease
signs. During disease progression, retinal microglia showed
a phenotype comparable to the pro-inflammatory one,
with less ramified morphology, and neurodegenerative-
associated markers, which can account for its neurotoxic
effects.
Extracellular and intracellular protein aggregates appear in
the retina of pre-symptomatic mice
Alternative activation of retinal microglia toward an
anti-inflammatory, neuroprotective phenotype in 3xTg-
AD mice at pre-symptomatic stage, may reflect an
increased tissue monitoring in response to early tissue
damage, due to very early accumulation of AD-related
protein aggregates.
We analyzed Aβ accumulation in retinal samples from
3xTg-AD mice by means of immunofluorescence. As
reported in Fig. 4a confocal analysis of Aβ staining
revealed that plaques started to appear in the retina of
5–10 PNWs 3xTg-AD mice in the RGC layer (IL; mini-
mum diameter: 580 nm), and that aggregate volume sig-
nificantly increased during disease progression. Aβ
staining was not observed in non-Tg retina of age-
matched controls (Fig. 4a). Moreover, we found that in
early-symptomatic mice, Aβ aggregated also in the outer
layers (OL) of the retina, increasing their volume in late-
stage mice (Fig. 4b). Co-immuno staining of Aβ and Iba1
revealed that in the retina of pre-symptomatic AD mice,
Fig. 2 Glial cells density is differently modulated during AD progression. a Retinal slices were immunolabeled with anti-GFAP antibody (green)
and Hoechst for nuclei visualization (blue) at different ages of 3xTg-AD and non-Tg mice and density of GFAP signal was quantified as shown in b
(**p < 0.01 pre vs early; n= 16 fields/four slices for each condition; two-way ANOVA, Holm-Sidak; ##p < 0.01 for comparison with age-matched non-Tg
mice, two-way ANOVA, Holm-Sidak). c Representative multiarea image of retinal slice immunolabeled with anti-Iba1 antibody (green) and Hoechst
for nuclei visualization (blue); density of Iba1+ cells was quantified as shown in d (**p < 0.01 vs 3xTg-AD pre; ##p < 0.01 vs age-matched non-Tg mice,
n= 16 fields/four slices for each condition, two-way ANOVA, Holm-Sidak method for multiple comparison)
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microglia processes directly contacted Aβ plaques
(Fig. 4c), suggesting that initial Aβ deposition is a signal-
inducing enhanced microglia tissue monitoring.
Similarly, using a specific antibody against pTau, we
detected pTau tangles in the RGC layer (IL) of 5–10
PNWs 3xTg-AD mice (minimum diameter: 680 nm).
Tangle volume significantly increased (Fig. 4e) and tangles
appeared in the outer layers (OL) of the retina during
disease progression (Fig. 4d). No signal was found in non-
Tg retinas (Fig. 4d). Moreover, as previously reported we
found Aβ plaques and pTau tangles in hippocampal
region already in pre-symptomatic mice, with volume
increase during disease progression. Remarkably, the
increase over time of Aβ plaques and pTau tangles
volume was correlated with what was observed in the
retina (Fig. 4f, g). Altogether, these data indicate that Aβ
plaques and pTau tangles are detectable in the retina of
young, pre-symptomatic mice, and contribute to glial
activation and neurodegeneration.
Discussion
Alzheimer’s disease represents nowadays the most
important cause of dementia, with high social and eco-
nomic costs; moreover, no specific cure counteracting
neurodegeneration is currently available and some
companies also retired their funding on AD-related
clinical research. For these reasons, there is an urgent
need to find new strategies for the diagnosis and the
treatment of AD. In this framework, we consider
retinal tissue as one of the best candidates that could
recapitulate the AD-related neurodegenerative process
happening in the brain, so we propose it as an easily
attainable tissue for the early diagnosis and the follow-up
of new therapies.
Fig. 3 Microglia activation state changes already at pre-symptomatic stage in 3xTg-AD mice. Representative skeletonized images of Iba1+
microglial cell in retinal slices of a 3xTg-AD and b non-Tg mice. c Morphological parameters analyzed for microglia cells at different stages of AD
show a more ramified retinal microglia morphology already at pre-symptomatic stage (**p < 0.01 vs 3xTg-AD pre; ##p < 0.01 vs age-matched non-Tg
mice; n= 40, two-way ANOVA). d Gate strategy for retinal microglia cells sorting. Real-time experiment for the mRNA expression of e anti- and f pro-
inflammatory genes and g TREM-2; data are mean ± s.e.m. of four different experiments and expressed as fold-increased expression of 3xTg-AD mice
vs. respective age-matched non-Tg mice (*p < 0.05 vs respective non-Tg value)
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For this reason, we investigated the appearance of
AD signs as neurodegeneration, intracellular and
extracellular protein aggregates, and neuroinflammation,
along the disease progression using a mouse model
(3xTg-AD) which recapitulates most of the AD
characteristics21.
We found, in 3xTg-AD mice, the presence of Aβ pla-
ques and pTau tangles, ganglion neuron degeneration,
astrogliosis and microglia activation, already at pre-
symptomatic stage, making the retina a good candidate
to be a window through which follow up the neurode-
generation process.
We here report, for the first time, that Aβ plaques and
pTau tangles were present in the retina of young (5–20
PNWs) non-symptomatic 3xTg-AD mice in the RGC.
Moreover, during disease progression (30–40 PMWs), in
Fig. 4 Amyloid beta plaques and pTau tangles are present in the retinas of pre-symptomatic 3xTg-AD mice. a Representative images of
retinal slices immunolabeled with anti-Aβ antibody (red) and Hoechst for nuclei visualization (blue) at different ages of 3xTg-AD and non-Tg mice;
plaque dimension was quantified as shown in b (**p < 0.01 vs pre in the inner layer; ##p < 0.01 vs early in the outer layer, n= 16 fields/four slices for
each condition). c Representative image of retinal slice immunolabeled with anti-Aβ antibody (red), Iba1 (green), and Hoechst for nuclei visualization
(blue), indicating that microglia is strictly connected to Aβ plaques emerging in retinal layers. d Representative images of retinal slice immunolabeled
with anti-pTau antibody (red) and Hoechst for nuclei visualization (blue) at different ages of 3xTg-AD and non-Tg mice; tangles dimension was
quantified as shown in e (**p < 0.01 vs pre in the inner layer; ##p < 0.01 vs early in the outer layer, n= 16 fields/four slices for each condition). f
Correlation plot of Aβ plaque volume in hippocampal area (x axis) vs retina (y axis) of 3xTg-AD mice during disease progression; n= 16 fields/four
slices for each condition, data are mean cumulative of different PNWs referred to the same AD stage; correlation coefficient: pre 0.531, early 1.00, late
0.916. g Correlation plot of pTau tangle volume in hippocampal area (x axis) vs retina (y axis) of 3xTg-AD mice during disease progression; n= 16
fields/four slices for each condition, data are mean cumulative of different PNWs referred to the same AD stage; correlation coefficient: pre 0.597,
early 1.00, late 0.909
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line with previous reports13,32–34, plaques and tangles
appear also in the inner retinal layers.
Consistently with the appearance of plaques and tangles
deposition, we show that neuronal apoptosis starts in the
retina of young non-symptomatic 3xTg-AD mice, pre-
dominantly in RGC layer, and that the time course of
neurodegeneration runs parallel to what is observed in the
brain, thus making the presence of protein aggregates and
neurodegeneration in the retina at non-symptomatic stage
a possible pre-symptomatic AD biomarker.
We also analyzed retinal inflammatory microenviron-
ment and the results herein indicate that glia (astrocytes
and microglia) activation starts in the 3xTg-AD mouse
retina at pre-symptomatic AD stage, with different acti-
vation timescales. Indeed, reactive GFAP-positive astro-
cytes are present in the 3xTg-AD retina already at 5–10
PNWs, much earlier than at 9 months, as previously
reported17,35. Regarding microglia, we found that micro-
glia density increased in 3xTg-AD retina only at late
disease stages, while no changes were observed in non-Tg
mice. On the other hand, microglia phenotype differs
from control and AD mice already at 1–2 months of age.
Indeed, we show that retinal microglia of young 3xTg-AD
mice (5–10 PNWs) display, respect to their age-matched
control, higher ramified morphology and expression of
anti-inflammatory markers, suggesting microglia pre-
activation with increased tissue monitoring and phago-
cytosis in response to first Aβ and pTau deposition in the
RGC. We can speculate that different activation states of
microglia cells may reflect in subtle morphological
changes in branching and/or distribution and this could
be due to the first appearance of protein aggregates that
triggers microglia response to the disease. Making a
longitudinal analysis during disease progression, we
observed that in the early-symptomatic period (30–40
PNWs) retinal 3xTg-AD microglia acquired a less rami-
fied morphology, in line with previously reported data36.
This was paralleled, in our study, by a partial decrease of
anti-inflammatory and increase of pro-inflammatory
markers, together with TREM-2 upregulation, indicative
of possible microglia switch from the homeostatic state to
the neurodegenerative-associated one31.
Altogether, these data indicate that molecular and cel-
lular determinants typical of AD are present in the retina
of young 3xTg-AD mouse model, making the retina the
ideal nervous tissue for early AD diagnosis and for
studying AD pathology and treatment efficacy.
This observation may suggest the possibility that ocular
biomarkers could be used for early detection of AD-
associated neurodegeneration; however, whether the
retina could be used to make a specific diagnosis of early,
pre-symptomatic AD, and monitor AD progression, is still
a matter of discussion. Indeed, while retinal examination
performed as fundus images, following oral curcumin
administration, revealed curcumin-positive retinal protein
aggregate spots in live AD patients37, AD diagnosis still
requires a combination of many biomarkers with a high
degree of clinical signs to correlate cognitive deficits to
retinal protein aggregates. Moreover, it should be con-
sidered that (i) curcumin binding is not specific for Aβ, (ii)
amyloid aggregates are found also in macular degenera-
tion38, and (iii) available retinal fundus examination does
not allow the detection of structures in the sub-
micrometric scale. Indeed, as shown for 3xTg-AD mice,
the use of protein aggregates (Aβ and pTau) as early
diagnostic biomarkers requires a submicron lateral reso-
lution (see results and Fig. 4). Thus, a huge improvement
is needed in developing both specific Aβ and pTau ligands
and long-working distance high-resolution imaging
techniques to make possible a non‐invasive and inex-
pensive diagnosis of AD through the retinal scan in live
patients.
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